Compare Medikit Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 6.42%
- The company has been able to generate a Return on Equity (avg) of 6.42% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 6.42%
3
Poor long term growth as Net Sales has grown by an annual rate of 4.20% and Operating profit at 3.58% over the last 5 years
4
Negative results in Mar 26
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 44,543 Million (Small Cap)
14.00
NA
0.00%
-0.48
6.43%
0.95
Revenue and Profits:
Net Sales:
5,315 Million
(Quarterly Results - Mar 2026)
Net Profit:
769 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.2%
0%
6.2%
6 Months
1.22%
0%
1.22%
1 Year
-2.25%
0%
-2.25%
2 Years
16.1%
0%
16.1%
3 Years
19.38%
0%
19.38%
4 Years
-10.82%
0%
-10.82%
5 Years
-22.34%
0%
-22.34%
Medikit Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.20%
EBIT Growth (5y)
3.58%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
0.50
Tax Ratio
33.38%
Dividend Payout Ratio
48.46%
Pledged Shares
0
Institutional Holding
0.14%
ROCE (avg)
22.48%
ROE (avg)
6.42%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.98
EV to EBIT
5.08
EV to EBITDA
3.54
EV to Capital Employed
0.96
EV to Sales
0.97
PEG Ratio
1.15
Dividend Yield
NA
ROCE (Latest)
18.84%
ROE (Latest)
6.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.14%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
5,315.40
5,211.20
2.00%
Operating Profit (PBDIT) excl Other Income
1,180.90
1,349.20
-12.47%
Interest
1.90
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
769.20
858.10
-10.36%
Operating Profit Margin (Excl OI)
115.50%
164.40%
-4.89%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 2.00% vs 4.44% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -10.36% vs -8.49% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
23,781.50
22,553.20
5.45%
Operating Profit (PBDIT) excl Other Income
6,310.40
6,175.10
2.19%
Interest
7.70
0.00
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
3,006.10
3,013.50
-0.25%
Operating Profit Margin (Excl OI)
179.60%
198.90%
-1.93%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 5.45% vs 3.22% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -0.25% vs -1.82% in Mar 2025
About Medikit Co., Ltd. 
Medikit Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






